PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes

Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title:Molecular Insights into HR+/HER2+Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint genomic subtypes Background: Clinical HER2+ (cHER2+) early breast cancer (EBC) represents 15-20% of invasive EBC and is typically Read More

Association of ImPrintTN Signature With Survival Outcomes by Race in Basal-Type Triple Negative Breast Cancer

Publication: ASCO® 2025 Authors: Priyanka Sharma, Shane R. Stecklein, Denise M. Wolf, Christina Yau, Laura Esserman, Laura van t Veer, David B. Page, Harshini Ramaswamy, Sahra Uygun, Josien Haan, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy Title: Association of ImPrintTN signature with survival outcomes by race in Basal-Type Read More

The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis

Publication: ESMO Breast Cancer 2025 Authors: Brufsky, et al. Title: The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis Background: The BluePrint (BP), 80-gene signature, provides insight into the intrinsic subtype of early-stage breast cancer (EBC). This study evaluates Read More

Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting

Publication: ASBRS 2025Authors: Thompson et al.Title: Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant settingIntroduction:Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and N-stageThe ACOSOG Z00111 trial found Read More

Successful Unconventional Precision Treatment of Inflammatory Hormone Receptor-Positive Breast Cancer Guided by Molecular Profiling

Publication: npj Precision Oncology | (2025) 9:63 Authors: Jailan Elayoubi , Yu Zong & Erich J. Schwartz Title: Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling Abstract: We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth Read More

Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX

Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrint® Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: • Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More